World's First Endovascular Neuromodulation Device Implanted in Man for the Treatment of Congestive Heart Failure

CAESAREA, Israel, November 5, 2015 /PRNewswire/ --

Enopace Biomedical, a developer of minimally invasive, implantable endovascular neuromodulation therapy for heart failure patients, announced today the first successful human implantation of its Harmony™ System, a catheter-based neurostimulator device to treat patients with congestive heart failure.

The procedure was successfully performed by Professor Davor Milicic, head of Cardiology at Zagreb Medical University and his team, on a NYHA class III heart failure patient. Additional patients are being enrolled in the clinical study at several other leading hospitals in Europe towards CE marking certification.

"We welcomed this great opportunity to work with the Enopace team in order to provide this breakthrough, innovative minimally invasive treatment for CHF patients," Professor Milicic commented.

Enopace's advanced technology consists of a leadless implantable catheter-based neurostimulator for heart failure patients, which increases cardiac efficiency by reducing left ventricular workload.

Heart failure is the largest untreated clinical need with the highest associated healthcare costs in the cardiovascular world today.

"The Harmony™ neuromodulation system represents a significant opportunity of a device-based therapy for heart failure" said Amir Dagan, Enopace's CEO. "It is the first neuromodulation device operating inside a blood vessel and modulating the autonomic balance of heart failure patients. The unique device uses cutting-edge technology of a leadless, active miniature stimulator and is implanted in a 30-minute percutaneous procedure."

"We are very pleased with this achievement and the implantation of this breakthrough technology which expands treatment options for heart failure patients," said Efi Cohen Arazi, CEO of Rainbow Medical and chairman of the board of Enopace Biomedical.

About Enopace Biomedical  

Enopace Biomedical, based in Caesarea, Israel, is developing an implantable, miniature neurostimulation device for congestive heart failure patients.

The company was founded in 2008 by Rainbow Medical (http://www.rainbowmd.com ), a unique private operational investment company that seeds and grows start-up companies developing breakthrough medical devices invented by Yossi Gross, in a diverse range of medical fields. By addressing significant unmet market needs, Rainbow Medical seeks to improve people's lives and generate exceptional returns for its shareholders.

For more information please contact: Meital Levi Tal, +972-54-7739677, [email protected]

SOURCE Enopace Biomedical